Cytokinetics to provide an update on cardiac myosin modulation programs

Cytokinetics will provide an update on the company’s cardiac myosin modulation programs and global commercial launch readiness for aficamten at its Investor and Analyst Day, “Heart Forward: Advancing Cardiac Myosin Modulation.” The Company plans to synthesize recent updates from clinical trials relating to aficamten, a next-in-class cardiac myosin inhibitor, as well as share the design of COMET-HF, a confirmatory Phase 3 clinical trial of omecamtiv mecarbil, a cardiac myosin activator being developed for the potential treatment of patients with symptomatic heart failure and severely reduced ejection fraction, and the design of AMBER-HFpEF, a Phase 2 clinical trial of CK-4021586, another cardiac myosin inhibitor being developed for the potential treatment of patients with symptomatic heart failure with preserved ejection fraction and hypercontractility.